The Bill & Melinda Gates Foundation announced grants totaling $258 million to develop a malaria vaccine
On Oct. 30, 2005, the Bill & Melinda Gates Foundation announced three grants totaling $258.3 million for advanced…
-
-
Federal Medicare rule required all long-term care facilities to offer vaccination for influenza and pneumococcal disease
On Oct. 7, 2005, a new Federal Medicare rule became effective that required all long-term care facilities to…
-
The genome of the 1918 H1N1 pandemic influenza virus was sequenced
On Oct. 7, 2005, Jeffery Taubenberger, AH Reid, AE Krafft, Karen Bijwaard and Thomas Fanning published a report…
-
A vaccine that combined the measles, mumps, rubella, and varicella antigens was licensed
On Sept. 6, 2005, the vaccine that combined the measles, mumps, rubella, and varicella antigens (Proquad by Merck)…
-
An inactivated, injectable influenza vaccine was licensed
On Aug. 31, 2005, the inactivated, injectable influenza vaccine (Fluarix) by GlaxoSmithKline (GSK) was licensed. The vaccine was…
-
FDA approved lowering the age limit to 12 mos for one of the two licensed hepatitis A vaccine
On Aug. 11, 2005, the Food and Drug Administration (FDA) approved an application of a pediatric/adolescent formulation of…
-
Corixa Corp. was acquired by Glaxosmithkline for $300 million
On Jul. 12, 2005, Corixa Corp., based on First Hill in Seattle, was acquired by Glaxosmithkline (GSK) for…
-
FDA licensed a 2nd Tdap vaccine (Adacel by Sanofi Pasteur) for use in persons ages 11-64 years
On Jun. 9, 2005, the U.S. Food and Drug Administration (FDA) announced it had expanded the approved age…
-
Cellular pertussis vaccine combined with adult formulation of tetanus and diphtheria licensed in persons 10-18 years of age
On May 3, 2005, the cellular pertussis vaccine combined with the adult formulation of tetanus and diphtheria (Tdap:…
-
Sanofi Pasteur announced FDA approval of Menactra meningococcal conjugate vaccine indication for infants
On Apr. 22, 2005, Sanofi Pasteur announced the U.S. Food and Drug Administration (FDA) had granted licensure to…
-
50th anniversary of the Salk Polio vaccine
On Apr. 12, 2005 marked the 50th anniversary of the announcement that the polio vaccine, developed by Jonas…
-
HHS awarded a contract for $97 million to Sanofi Pasteur to develop cell culture-based influenza vaccines for the U.S.
On Apr. 1, 2005, Sanofi pasteur was awarded a five-year $97 million contract from the U.S. Department of…
-
The first meningococcal polysaccharide diphtheria toxoid conjugate vaccine (Menactra by Sanofi Pasteur) was licensed
On Jan. 14, 2005, the first meningococcal polysaccharide (Serogroups A, C, Y and W-135) diphtheria toxoid conjugate vaccine…
-
OHSU was awarded $4 million NIH biodefense contract to study tuberculosis
On Nov. 1, 2004, an Oregon Health & Science University (OHSU) research team announced that it was one…
-
Biotechnology | Diagnostics | Infectious Disease | NIH | Non-Profit Research | Therapeutics | Vaccine
PNNL lands $10.3 million NIH biodefense contract to unlock proteomes of salmonella and pox
On Sept. 14, 2004, Pacific Northwest National Laboratory (PNNL) announced it had received a $10.3 million biodefense contract…
-
A significant shortage of influenza vaccine occurred in the U.S.
On Aug. 25, 2004, a significant shortage of influenza vaccine occurred in the U.S. as a result of…
-
The 8th and final report of the Immunization Safety Review Committee was issued by the Institute of Medicine
On Jun. 26, 2004, the eighth and final report of the Immunization Safety Review Committee examines the hypothesis…
-
Contracts awarded to Aventis Pasteur and Chiron to develop vaccine against H5N1 avian influenza virus
On May 27, 2004, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had awarded contracts…
-
OHSU VGTI received a $3.5 million NIH grant to assist in development of AIDS vaccine
On May 25, 2004, researchers at the Vaccine and Gene Therapy Institute (VGTI) and the Oregon National Primate…
-
Biotechnology | NIH | Vaccine
NIAID awarded a new license agreement for RotaShield, an oral rotavirus vaccine
On May 4, 2004, the National Institute of Allergy and Infectious Diseases (NIAID), awarded a new license agreement…
-
The National incident Management System was established to coordinate response for public health incidents
On Mar. 1, 2004, the National incident Management System (NIMS), developed by the Department of Homeland Security (DHS),…
-
Rubella was declared eliminated in the U.S.
In 2004, Rubella, also known as German measles, was declared eliminated in the U.S. Before the rubella vaccination…
-
The University of Georgia Cancer Center was established
In 2004, the University of Georgia Cancer Center was established, specializing in drug targets, diagnostic tests, cancer vaccines,…
-
ACIP voted to recommend influenza vaccination for children aged 6 to 23 months
On Oct. 15, 2003, the Immunization Practices Advisory Committee (ACIP) voted to recommend that children 6 to 23…
-
Biotechnology | HIV | Infectious Disease | NIH | Vaccine
$81 million was awarded by NIAID through four new contracts to support development of candidate HIV vaccines
On Sept. 29, 2003, $81 million was awarded by National Institute of Allergy and Infectious Diseases (NIAID) through…
-
OHSU announced results of a smallpox vaccine study on America’s preparedness for a smallpox outbreak
On Aug. 17, 2003, Oregon Health & Science University (OHSU) announced the final results of a smallpox vaccine…
-
Biotechnology | CDC | Diagnostics | Genomics | Infectious Disease | Therapeutics | Vaccine
The CDC responded to U.S. outbreak of mpox, first human Mpox outside of Africa
On Jul. 8, 2003, the U.S. Centers for Disease Control and Prevention (CDC) announced a total of 71…
-
The first nasally administered influenza vaccine (FluMist by MedImmune) was licensed
On Jun. 17, 2003, the U.S. Food and Drug Administration (FDA) announced it had approved FluMist. This was…
-
Biotechnology | CDC | COVID-19 | Diagnostics | Genomics | Infectious Disease | Non-Profit Research | Therapeutics | Vaccine
Michael Smith Genome Science Centre sequenced the SARS genome
On Apr. 14, 2003, researchers at Canada’s Michael Smith Genome Science Centre in Vancouver announced they had sequenced…
-
Severe Acute Respiratory Syndrome (SARS) was placed on U.S. quarantine list
On Mar. 18, 2003, Severe Acute Respiratory Syndrome (SARS) was placed on U.S. quarantine list. Persons under quarantine…
